Key result
The ALLHAT study enrolled 15,297 high-risk hypertensive adults with diabetes to evaluate the efficacy of chlorthalidone versus amlodipine, lisinopril, or doxazosin.
Why the study?
Do alternative antihypertensive therapies (amlodipine, lisinopril, doxazosin) compared to chlorthalidone reduce fatal and nonfatal CHD and combined cardiovascular events in hypertensive adults with diabetes?
Cohort (n=15,297)
Yes
Do alternative antihypertensive therapies (amlodipine, lisinopril, doxazosin) compared to chlorthalidone reduce fatal and nonfatal CHD and combined cardiovascular events in hypertensive adults with diabetes?
This baseline report describes a large, diverse cohort of older diabetic patients with hypertension in the ALLHAT trial, which will provide valuable information on optimal antihypertensive therapy in this high-risk population.
Answers are grounded in this paper and cite their sources.
Baseline characteristics of this large diabetic hypertensive cohort are detailed; leaves open comparative efficacy of regimens pending outcome data.
OBJECTIVE: Hypertension (HTN) is a major risk factor for cardiovascular disease (CVD) in the setting of diabetes. There is no consensus on how best to treat hypertension among those with diabetes. Here we describe the characteristics of a cohort of hypertensive adults with diabetes who are part of a large prospective blood pressure study. This study will help clarify the treatment of HTN in the setting of diabetes. RESEARCH DESIGN AND METHODS: The Antihypertensive and Lipid-Lowering high-risk hypertensive participants, ages > or = 55 years, designed to determine whether the incidence of fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events (fatal and nonfatal CHD, revascularization surgery, angina pectoris, congestive heart failure, and stroke) differs between diuretic (chlorthalidone) treatment and three alternative antihypertensive therapies: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin). The planned follow-up is an average of 6 years, to be completed March 2002. RESULTS: There are 15,297 diabetic individuals in the ALLHAT study (36.0% of the entire cohort). Of these individuals, 50.2% are male, 39.4% are African-American, and 17.7% are Hispanic. Demographic and laboratory characteristics of the cohort are similar to those of other studies of the U.S. elderly population with HTN. The sample size has 42 and 93% confidence, treatments for the two study outcomes. CONCLUSIONS: The diabetic cohort in ALLHAT wil be able to provide valuable information about the treatment of hypertension in older diabetic patients at risk for incident CVD.
No takes yet. Share an insight, caveat, or question.
Barzilay et al. (2001) conducted a cohort in Hypertension and diabetes (n=15,297). Diuretic (chlorthalidone) vs. Calcium channel blocker (amlodipine), ACE inhibitor (lisinopril), and alpha-adrenergic blocker (doxazosin) was evaluated on Fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events. The ALLHAT study enrolled 15,297 high-risk hypertensive adults with diabetes to evaluate the efficacy of chlorthalidone versus amlodipine, lisinopril, or doxazosin.
Synapse has enriched 10 related papers. Consider them for comparative context: